[{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Tarloxotinib Bromide","moa":"EGFR\/HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tarloxotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tarloxotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Rain Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Rain Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Rain Oncology \/ Rain Oncology"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Rain Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Rain Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Rain Oncology"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Guggenheim Securities"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Boxer Capital","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Boxer Capital"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Pathos","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Pathos"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Pathos","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Pathos"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RAIN-32","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RAIN-32","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rain Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Rain Oncology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
